Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery

Overview

To-date there have been only very few studies to examine the effect of cataract surgery to patients with wet age-related macular degeneration. The evidence on the effects of cataract surgery in such patients suggests improvement of their visual function and quality of life, but at the same time a subclinical susceptibility to macular edema and exacerbation of the choroidal neovascularization. Therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

Full Title of Study: “Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery: A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2020

Detailed Description

To-date there have been only very few studies to examine the effect of cataract surgery to patients with neovascular age-related macular degeneration (AMD), especially in the era of anti-vascular endothelial growth factor (anti-VEGF) therapy. Furthermore the issue of optimum treatment regimen that should be used in the peroperative period has never been addressed. Since the human life expectancy gradually increases, the number of patients who are under anti-VEGF intravitreal injections for wet AMD will be increasing accordingly. Cataract surgery in such patients, despite guarded prognosis has been proved to improve their visual function and quality of life. On the other hand, it has been shown that cataract surgery induces anatomic changes based on optical coherence tomography analysis, suggesting a subclinical susceptibility to postoperative cystoid macular edema or exacerbation of choroidal neovascularization. Therefore it is highly important to identify the optimum treatment regime, pursuing the best anatomical and functional postoperative results.

Interventions

  • Drug: Ranibizumab
    • Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.

Arms, Groups and Cohorts

  • Active Comparator: Intensive Treatment
    • The participants will receive x1 intraoperative and 3 postop monthly injections. Subsequently, they will follow the treat and extend protocol.
  • Active Comparator: Standard Treatment
    • The participants will continue their preoperative treat and extend protocol .

Clinical Trial Outcome Measures

Primary Measures

  • Visual acuity change from baseline
    • Time Frame: 12 months
    • Difference in visual acuity change from baseline at the end of the follow-up period.
  • Difference in the number of injections
    • Time Frame: 12 months
    • Difference in the number of injections at the end of the follow-up period.

Secondary Measures

  • Status of the macular degeneration based on optical coherence tomography parameter, as compared to baseline
    • Time Frame: 12 months
    • The status of the age-related macular degeneration will be evaluated based on optical coherence tomography parameters at the at final follow-up and compared to the baseline. Our main focus is to identify any subfoveal scarring and/ or subfoveal atrophy that may develop during the follow-up and assess changes from the baseline state of the macula.

Participating in This Clinical Trial

Inclusion Criteria

  • Active choroidal neovascularization (at least 1 intravitreal injection in the past 12 months) associated with AMD and involving the foveal center
  • BCVA of 1.0 (LogMAR) or better
  • Duration of wet AMD less than 3 years

Exclusion Criteria

  • Coexisting ocular pathology potentially affecting visual acuity and/or status of the macula including diabetic retinopathy, advanced glaucoma, retinal vein occlusion, retinal detachment
  • Newly diagnosed patients with wet AMD who are on anti-VEGF treatment for less than 6 months

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ophthalmica Eye Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Paris G Tranos, PhD, Principal Investigator, Head of Uveitis & Retinal Surgery Department, Ophthalmica Eye Institute
  • Overall Contact(s)
    • Paris G Tranos, PhD, 00302310263063, tranos@ophthalmica.gr

References

Kessel L, Erngaard D, Flesner P, Andresen J, Tendal B, Hjortdal J. Cataract surgery and age-related macular degeneration. An evidence-based update. Acta Ophthalmol. 2015 Nov;93(7):593-600. doi: 10.1111/aos.12665. Epub 2015 Jan 20. Review.

Saraf SS, Ryu CL, Ober MD. The effects of cataract surgery on patients with wet macular degeneration. Am J Ophthalmol. 2015 Sep;160(3):487-492.e1. doi: 10.1016/j.ajo.2015.06.006. Epub 2015 Jun 19.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.